Acurx Pharmaceuticals, Inc. 8-K

What Happened

• Acurx Pharmaceuticals, Inc. filed an 8-K on March 9, 2026 announcing voluntary reductions to executive base salaries and a 10% reduction to cash components of its non-employee director compensation program, each effective April 1, 2026. After the 10% salary reduction, annual base salaries will be: David P. Luci (President & CEO) $495,000; Robert J. DeLuccia (Executive Chairman) $495,000; Robert G. Shawah (CFO) $360,000.
• The company also announced a new clinical development initiative to expand its antibiotic candidate ibezapolstat into recurrent C. difficile infection (rCDI), beginning with an open-label pilot trial of up to 20 patients. Site start-up activities are scheduled to begin later in March 2026, with first-patient enrollment expected in Q4 2026.

Key Details

• Executive base salary reductions are voluntary, approved by the Compensation Committee, and affect only base salary (other employment terms unchanged). Target annual bonuses will remain expressed as a percentage of base salary as in effect, and long-term equity awards are not impacted unless the Committee decides otherwise.
• Director cash reductions: 10% cut to annual cash retainers and additional cash retainers for Board Chair and committee chairs/members (equity components for directors remain unchanged).
• rCDI pilot trial: open-label, up to 20 patients who have had at least two C. difficile recurrences in the prior 12 months; data from this study will inform design of a planned active-controlled Phase 3 registration trial.
• Regulatory path: following a successful pivotal Phase 3, Acurx plans to seek FDA approval under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) for treatment and prevention of rCDI.

Why It Matters

• Cost and cash management: the voluntary 10% base-salary cuts for senior executives and 10% reduction in director cash retainers indicate management actions to lower near-term cash burn; this can modestly extend runway or free resources for operations without altering equity incentive plans.
• Clinical strategy: expanding ibezapolstat into rCDI and running a small pilot are early but material clinical steps that, if successful, would support a Phase 3 program and a potential LPAD regulatory route — important milestones that could affect the drug’s commercial opportunity and future company valuation.
• Timing and risk: the pilot is small and early-stage (20 patients), so meaningful clinical or regulatory outcomes remain some time away; investors should view these as developmental updates rather than immediate revenue drivers.